EULAR 2018 - Day 3 Report

Save

Day 3 highlights include Behcet’s responds to apremilast and that biologics do not differentially affect TKR/THR post-operative infection rates. Be sure to check out today's podcast as well. 

High Biologic Blood Levels Increases the Risk of Infections in RA

Save

A big concern of most is the risk of infection with use of tumour necrosis factor inhibitor (TNFi) and biologic drugs.  While studied in both trials and in post-marketing studies, it is unknown if infection risk is dose-dependent.

EULAR 2018 - Day 2 Report

Save

Highlights from Day 2 of the EULAR meeting in Amsterdam include high MBDA scores in ACPA negative RA predicts remission; characterization of difficult RA; and gender differences in psoriatic responses to TNF inhibitors. 

Biosimilar Data at #EULAR2018

Save

Biosimilars are here, and more are being registered all the time, so I was really interested in the biosimilar data at the meeting.

Abbvie Highlights Upadacitinib Trials at EULAR18

Save

Abbvie press releases feature the results from 3 new trials to be presented during the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam from three Phase 3 trials evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderat

EULAR 2018 - Day 1 Report

Save

Highlights from the first day at EULAR include: canakinumab prevents acute gout; AS uveitis benefits from most TNFi; MRI does not improve T2Tor X-ray outcomes; baracitinib wins in SLE - maybe?; new lupus criteria; and lost survival in RA. Here's the RheumNow recap. 

Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)

Save

Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.

Vedolizumab Implicated in Exacerbations of SpA in IBD Patients

Save

Beloved by gastroenterologist for treatment of inflammatory bowel disease (IBD), α4β7 integrin receptor vedolizumab (VDZ) has probably caught attention of many rheumatologist since the time it entered the market; largely for what it won't do for inflammatory arthritis.

Risk of Psoriasis Complicating TNF Inhibitor Therapy

Save

A population-based study of claims data from Korea shows that among inflammatory bowel disease (IBD) patients receiving tumour necrosis factor inhibitors (TNFi) there is a 3.7 per 100 patient-year risk of paradoxically developing psoriasis - a rate that is roughly 3-fold higher than risk in TNFi-naive IBD patients.

The RheumNow Week in Review – Baricitinib Splash (6.7.18)

Save

Dr. Jack Cush discusses the past week's news and journal articles featured on RheumNow.com - including reports on advance practice clinicians, baricitinib, gout, disease activity, hypomagnesemia and upadacitinib.

FDA Approves Low Dose Baricitinib for Rheumatoid Arthritis

Save

The US Food and Drug Administration has approved baricitinib (Olumiant) for use in adults in moderate-to-severe active rheumatoid arthritis (RA) who have had an inadequate response to TNF inhibitors (TNFi). It is not approved for use, nor has it been studied, in children.

FDA Approves Baricitinib 2 mg for Rheumatoid Arthritis

Save

Today the U.S. Food and Drug Administration approved baricitinib (Oluminant) at the lower dose of 2 mg per day for use in adults with with moderate-to-severe active rheumatoid arthritis (RA) who have had an inadequate response to commonly-used treatments known as TNF inhibitors.

The RheumNow Week in Review – Good News for GPA, CZP, Tofa but not ERA (6.1.18)

Save

Dr. Jack Cush reviews this weeks reports from RheumNow.com, including the risk of autoimmunity with vaccination, early RA outcomes, new FDA approvals for certolizumab and tofacitinib and the risk of death from infection with biologics.

Ustekinumab: A Novel Intervention in Giant Cell Arteritis

Save

Treatment of refractory giant cell arteritis (GCA) with ustekinumab (Stelara) showed therapeutic promise as a steroid-sparing agent in a small, open-label study, Irish researchers reported.

High anti-TNF Failure Rates with Obesity

Save

A meta-analysis has suggested that obesity is an under-reported predictor of inferior response to tumor necrosis factor blockade (anti-TNF) in a range of inflammatory immune-mediated inflammatory diseases (IMIDs), with the results showing a 60% risk of impaired response to anti-TNF across several

Cancer Risk Raised in Psoriatic Arthritis

Save

Patients with psoriatic arthritis (PsA) were at increased risks for malignancy, and possibly more so if they were treated with conventional disease-modifying antirheumatic drugs (DMARDs), a meta-analysis found.

In nine cohort studies that included more than 43,000 PsA patients, the pooled relative risk for overall malignancy was 1.29 (95% CI 1.04-1.60) compared with the general population, according to Yunyun Fei, MD, and colleagues from Peking Union Medical College in Beijing.

Tocilizumab Beats Anti-TNFs for Treatment Retention

Save

Patients with rheumatoid arthritis (RA) who had previously had an inadequate response to one biologic agent remained on tocilizumab (Actemra) longer than on a tumor necrosis factor (TNF) inhibitor, whether or not conventional disease modifying anti-rheumatic drugs (DMARDs) were given concomitantl

Targeting IL-17A: A Winner in PsA

Save

Psoriatic arthritis patients with inadequate response to tumor necrosis factor (TNF) inhibitors had improvements in their arthritis and psoriasis when treated with the interleukin (IL)-17A blocker ixekizumab (Taltz), according to a phase III study presented here at the

Genetic Breakthrough in Systemic JIA

Save

The identification of a genetic susceptibility locus for systemic juvenile idiopathic arthritis (sJIA) has important implications for treatment of this severe, poorly understood illness, researchers reported.

The RheumNow Week in Review – FDA Showdown for Baricitinib (4.27.18)

Save

Dr. Jack Cush reviews the news and FDA proceedings from the past week on RheumNow.com.